Skip to content
Protocolos

Safety and limits

Experimental material. Read before using anything from here.

Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.

Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.

Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.

The risk that does not appear in the dose table

Every table in this reference answers the question "how much". None answers the three that usually hurt first:

1. What is inside the vial

A product labeled "research use only" has not gone through identity, purity, sterility or endotoxin control for human use. The label says 10 mg; nobody guaranteed it is 10 mg, nor that it is the right compound, nor that it is sterile. A certificate of analysis (COA) from the supplier is better than nothing, but it is a document issued by whoever is selling.

2. The dose the community repeats

A good share of the numbers here come from community reports. A dose cited by a thousand people is still a report repeated a thousand times — it does not become evidence by accumulation. Where a published trial exists, the page says so. Where none exists, it says that too.

3. The interaction with what you already take

Several compounds on this list affect glucose, blood pressure, coagulation or serotonergic signaling. Methylene blue with an SSRI antidepressant is the most direct example: it is a risk of serotonin syndrome, not a nuisance. A professional who sees your entire medication list is the only serious way to resolve this.

Situations that call for stopping and seeking care

  • Persistent abdominal pain, especially with nausea or vomiting — heightened attention with incretin agonists and with VIP.
  • Any change in a mole: color, border, size or bleeding. Applies to Melanotan II in particular.
  • Shortness of breath, asymmetric leg swelling, chest pain.
  • Visual change, new and persistent headache, confusion.
  • Injection-site reaction that spreads, gets hot or comes with fever.
  • Hypoglycemia — tremor, cold sweat, confusion. Of particular concern with IGF-1 LR3.

Groups where the risk is different

Pregnancy, breastfeeding, active cancer or a history of cancer, kidney or liver disease, anticoagulant use, psychiatric disorder under treatment, and minors. None of the compounds in this reference has safety data that supports use in these contexts, and several have mechanistic reason for concern — systemic growth signaling is the clearest example.

Regulatory status in Brazil

None of the compounds marked "not approved" in this reference has registration for the purposes described. Semaglutide, tirzepatide and tesamorelin have registration for specific indications and require a prescription. Importing a research-use product for personal consumption does not turn it into a medicine — it only changes who carries the risk.

What this reference does not do

  • Does not point to suppliers, stores or brands. The original source has commercial links; they were removed.
  • Does not recommend a dose, cycle or combination to anyone.
  • Did not verify any primary source. The check was against the secondary source.
  • Does not replace a consultation, lab test or prescription.